公开(公告)号：US20210349096A1

公开(公告)日：2021-11-11

申请号：US16321745

申请日：2017-07-27

Applicant: THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM

Inventor： Chengcheng ZHANG ,  Zhiqiang AN ,  Ningyan ZHANG ,  Mi DENG ,  Jaehyup KIM ,  Xun GUI

IPC: G01N33/574 ,  G01N33/50 ,  G01N15/14 ,  G01N21/64

Abstract: Provided herein are methods and compositions for the identification of modulators of ApoE-induced LILRB activation. Also provided herein are methods of treating cancer comprising the administration of an inhibitor of ApoE-induced LILRB activation. Also provided are methods of treating autoimmune disease or inhibiting the onset of transplant rejection or treating an inflammatory disorder comprising administering an agonist of ApoE-induced LILRB activation to a subject.

公开(公告)号：US20190338026A1

公开(公告)日：2019-11-07

申请号：US16475223

申请日：2018-01-02

Applicant: THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM

Inventor： X. Charlene LIAO ,  Qiang LIU ,  Zhiqiang AN ,  Ningyan ZHANG ,  Xun GUI ,  Chengcheng ZHANG ,  Mi DENG ,  Jingjing XIE

IPC: C07K16/28 ,  C12N5/12 ,  C12N15/85

Abstract: The present disclosure is directed to antibodies binding to LAIR 1 and their treating cancer, inflammation, immune-related diseases or transplantation.

公开(公告)号：US20240101667A1

公开(公告)日：2024-03-28

申请号：US18255745

申请日：2021-12-02

Applicant: THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM

Inventor： Chengcheng ZHANG ,  Guojin WU ,  Jaehyup KIM ,  Heyu CHEN ,  Mi DENG ,  Zhiqiang AN ,  Ningyan ZHANG ,  Ryan HUANG

IPC: C07K16/28 ,  A61P35/02 ,  G01N33/574 ,  G01N33/577

CPC classification number: C07K16/2803 ,  A61P35/02 ,  G01N33/574 ,  G01N33/577 ,  A61K2039/505 ,  C07K2317/24 ,  C07K2317/76 ,  C07K2317/92

Abstract: Provided herein are methods and compositions for the identification of modulators of LILRB3 activation. Also provided herein are methods of treating cancer comprising the administration of an inhibitor LILRB3 activation. Also provided are methods of treating autoimmune disease or inhibiting the onset of transplant rejection or treating an inflammatory disorder comprising administering an agonist of LILRB3 activation to a subject.

公开(公告)号：US20230235055A1

公开(公告)日：2023-07-27

申请号：US18007185

申请日：2021-07-26

Applicant: THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM

Inventor： Zhiqiang AN ,  Chengcheng ZHANG ,  Ningyan ZHANG ,  Yuanzhi CHEN ,  Heyu CHEN

IPC: C07K16/28 ,  A61K45/06 ,  G01N33/574 ,  A61K39/395 ,  A61P35/00

CPC classification number: C07K16/2803 ,  A61K45/06 ,  G01N33/57484 ,  A61K39/3955 ,  A61P35/00 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/73 ,  A61K2039/505

Abstract: Provided herein are antibodies binding to LILRB1 and the uses of the antibodies in detecting and treating cancer and autoimmune diseases.

公开(公告)号：US20180086829A1

公开(公告)日：2018-03-29

申请号：US15696972

申请日：2017-09-06

Applicant: THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM

Inventor： Chengcheng ZHANG ,  Mi DENG ,  Wei XIONG ,  Zhiqiang AN ,  Ningyan ZHANG ,  Xun GUI ,  Junke ZHENG

IPC: C07K16/28 ,  C07K16/30 ,  A61P35/02 ,  A61K45/06 ,  A61K39/395 ,  G01N33/574

CPC classification number: C07K16/2803 ,  A61K39/3955 ,  A61K45/06 ,  A61K2039/505 ,  A61P35/02 ,  C07K16/3061 ,  C07K2317/14 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/33 ,  C07K2317/54 ,  C07K2317/55 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/622 ,  C07K2317/76 ,  C12N15/1138 ,  C12N2310/14 ,  C12N2310/531 ,  G01N33/57426 ,  G01N33/57492 ,  G01N2333/70503

Abstract: The present disclosure is directed to antibodies binding to LILRBs and methods of detecting and treating cancer therewith.

公开(公告)号：US20210179687A1

公开(公告)日：2021-06-17

申请号：US16762273

申请日：2018-11-06

Applicant: THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM

Inventor： Chengcheng ZHANG ,  Samuel JOHN ,  Heyu CHEN ,  Mi DENG ,  Xun GUI ,  Ningyan ZHANG ,  Zhiqiang AN

IPC: C07K14/705 ,  A61K45/06 ,  A61P35/02 ,  C12N5/0783

Abstract: The present disclosure provides methods and compositions for immunotherapy employing a modified T cell or NK cell comprising a chimeric LILRB4 antigen receptor (CAR) that can be administered to patients for disease (e.g., cancer) treatment.

公开(公告)号：US20230068663A1

公开(公告)日：2023-03-02

申请号：US17759800

申请日：2021-01-28

Applicant: THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM ,  IMMUNE-ONC THERAPEUTICS, INC.

Inventor： Zhiqiang AN ,  Ningyan ZHANG ,  Zhiqiang KU ,  Chengcheng ZHANG ,  Xiaoye XU ,  Heyu CHEN ,  JingJing XIE ,  Maria Jose COSTA ,  An SONG ,  X. Charlene LIAO

IPC: C07K16/28 ,  A61K45/06 ,  A61K47/68 ,  A61P35/02 ,  A61K39/395 ,  G01N33/574

Abstract: Provided herein are antibodies binding to LILRB2 and the uses of the antibodies in detecting and treating cancer and autoimmune diseases.

公开(公告)号：US20210371518A1

公开(公告)日：2021-12-02

申请号：US17275838

申请日：2019-09-12

Applicant: THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM ,  IMMUNE-ONC THERAPEUTICS, INC.

Inventor： Zhiqiang AN ,  Chengcheng ZHANG ,  Ningyan ZHANG ,  Xun GUI ,  Mi DENG ,  Tao HUANG ,  Qiang LIU ,  X. Charlene LIAO

IPC: C07K16/28 ,  A61P35/02 ,  A61K45/06 ,  A61K39/395 ,  A61K47/68 ,  A61K51/10 ,  G01N33/574 ,  A61K47/69

Abstract: The present disclosure provides an isolated monoclonal antibody or an antigen-binding fragment thereof that binds specifically to leukocyte immunoglobulin-like receptor 4 (LILRB4). In certain embodiments, the antibody or antigen-binding fragment, when bound to LILRB4, modulates the activation of LILRB4. In certain embodiments, the antibody or antigen-binding fragment, when bound to LILRB4, activates LILRB4. In certain embodiments, the antibody or antigen binding fragment, when bound to LILRB4, suppresses activation of LILRB4. In certain embodiments, the antibody or antigen-binding fragment, when bound to LILRB4, specifically blocks binding of ApoE to LILRB4. In another aspect, there is provided a method of treating or ameliorating the effects of a cancer in a subject, comprising administering to the subject a therapeutically effective amount of the antibody or an antigen-binding fragment thereof or an engineered cell as provided herein.

公开(公告)号：US20200079851A1

公开(公告)日：2020-03-12

申请号：US16678049

申请日：2019-11-08

Applicant: THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM

Inventor： Chengcheng ZHANG ,  Mi DENG ,  Wei XIONG ,  Zhiqiang AN ,  Ningyan ZHANG ,  Xun GUI ,  Junke ZHENG

IPC: C07K16/28 ,  G01N33/574 ,  C07K16/30 ,  A61K45/06 ,  A61K39/395 ,  A61P35/02 ,  C12N15/113

Abstract: The present disclosure is directed to antibodies binding to LILRBs and methods of detecting and treating cancer therewith.

公开(公告)号：US20180177847A1

公开(公告)日：2018-06-28

申请号：US15834004

申请日：2017-12-06

Applicant: The Board of Regents of the University of Texas System ,  Icahn School of Medicine at Mount Sinai

Inventor： Shu-Hsia CHEN ,  Chengcheng ZHANG ,  Xunlei KANG ,  Junke ZHENG ,  Masato UMIKAWA

IPC: A61K38/18 ,  G01N33/68 ,  A61K31/713 ,  A61K35/15 ,  A61K38/07 ,  A61K38/16 ,  A61K39/395 ,  A61K45/06 ,  A61K31/7105 ,  C07K16/28

CPC classification number: A61K38/1891 ,  A61K31/7105 ,  A61K31/713 ,  A61K35/15 ,  A61K38/07 ,  A61K38/16 ,  A61K39/3955 ,  A61K45/06 ,  C07K16/2803 ,  G01N33/6872 ,  G01N2333/515 ,  G01N2333/70503 ,  G01N2500/04 ,  G01N2800/24 ,  G01N2800/245 ,  G01N2800/7028 ,  G01N2800/7095 ,  A61K2300/00

Abstract: Provided herein are compositions and methods useful for increasing a pro-inflammatory immune response, treating an autoimmune disorder, inflammation, or transplant rejection in a mammal by activating a leukocyte immunoglobulin-like receptor (LILR) protein. Also provided are compositions and methods useful for increasing a pro-inflammatory immune response, treating cancer, and treating infectious disease in a mammal by blocking the activation of a LILR protein.